Please login to the form below

Not currently logged in
Email:
Password:

Esbriet

This page shows the latest Esbriet news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

years. Two drugs have been approved for IPF - Roche's Esbriet (pirfenidone) and Boehringer Ingelheim's Ofev (nintedanib) - but while they can delay disease progression neither has a significant impact on

Latest news

  • Cancer drugs help Roche beat expectations in first quarter Cancer drugs help Roche beat expectations in first quarter

    Esbriet (pirfenidone) for idiopathic pulmonary fibrosis and just-launched Alecensa (alectinib) for ALK-positive non-small cell lung cancer (NSCLC) also got off to a strong start - adding CHF172m and CHF29m,

  • Roche shares slip as profits miss expectations Roche shares slip as profits miss expectations

    Among its other big-selling drugs, Avastin (bevacizumab) grew 9% while Rituxan/MabThera (rituximab) added 4% despite increasing competition, and new idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) continued its impressive

  • Boehringer hails its 'landmark year' in respiratory Boehringer hails its 'landmark year' in respiratory

    This is very exciting news for Boehringer and for patients.”. Competition, however, will come from Roche's Esbriet (pirfenidone), which has shown to boost survival in patients with IPF and was

  • Roche says Esbriet boosts survival in pulmonary fibrosis Roche says Esbriet boosts survival in pulmonary fibrosis

    Meanwhile, Esbriet blocks the synthesis of TGF-beta, a chemical that controls many cell functions and plays a key role in fibrosis. ... Roche is also conducting a clinical trial of the combination of Esbriet and lebrikizumab - an anti-interleukin-13

  • Roche pharma sales strong for first half of 2015 Roche pharma sales strong for first half of 2015

    recently acquired with the purchase of US biotech InterMune - were also healthy, with Kadcyla up 65% to CHF362m and Esbriet CHF229m in its first six months under Roche. ... I am very encouraged by the strong uptake of our new medicine Esbriet, for

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The prize: the FDA designated “breakthrough therapy” pirfenidone (Esbriet), an orally active small molecule, anti-fibrotic agent that inhibits the synthesis of both TGF-beta and TNF-alpha. Pirfenidone is under

  • Orphan indication? No easy access Orphan indication? No easy access

    Only the case of Intermune's idiopathic pulmonary fibrosis drug Esbriet (perfenidone) was the balance of benefit and risk to patients considered and a finding of 'no proven added benefit' was

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Out of the 10 products assessed last year, four have obtained poor innovation scores: Esbriet (pirfenidone), Livazo (pitavastatin), Yellox (bromfenac) and Trajenta (linagliptin) and a majority of manufacturers have struggled – sometimes

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics